#monkey

Trials for HIV-positive people of a treatment using the CRISPR-Cas9 gene editing tool may be on the horizon.

Trials for HIV-positive people of a treatment using the CRISPR-Cas9 gene editing tool may be on the horizon.

A new long-acting injectables HIV drug shows promise in monkey study.

New mRNA vaccine approach protects monkeys from HIV-like virus.

The D-peptide HIV entry inhibitor CPT31 is being developed with hopes it could be injected quarterly for both treatment and prevention.

Merck’s investigational antiretroviral is a reverse transcriptase translocation inhibitor.

Researchers are looking for ways to reduce the doses needed for on-demand PrEP and the 30-day duration recommended for PEP.

Researchers have been searching for agents that can wake HIV from its resting state in an effort to flush out the viral reservoir.

Researchers infected 1-month-old primates with HIV-like virus and 30 hours later injected them with a pair of antibodies.

A key mutation protected humans against simian HIV for millennia.

Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.

It likely aided the human species’s expansion but was eventually outmatched by an evolving virus.

Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against HIV.

The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.

The insert contained the antiretrovirals tenofovir alafenamide, known as TAF, and Vitekta (elvitegravir).

In a recent small trial, researchers have been unable to detect viable virus in the tissues of two monkeys that received the treatment.